VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Profitability
This table compares VYNE Therapeutics and NRx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VYNE Therapeutics | -6,896.55% | -43.73% | -38.55% |
| NRx Pharmaceuticals | N/A | N/A | -449.16% |
Earnings and Valuation
This table compares VYNE Therapeutics and NRx Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VYNE Therapeutics | $501,000.00 | 46.75 | -$28.45 million | ($0.94) | -1.64 |
| NRx Pharmaceuticals | N/A | N/A | -$30.15 million | ($2.41) | -0.75 |
Institutional & Insider Ownership
83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.8% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for VYNE Therapeutics and NRx Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VYNE Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| NRx Pharmaceuticals | 0 | 0 | 4 | 1 | 3.20 |
VYNE Therapeutics currently has a consensus target price of $6.88, suggesting a potential upside of 346.43%. NRx Pharmaceuticals has a consensus target price of $28.25, suggesting a potential upside of 1,460.77%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than VYNE Therapeutics.
Volatility and Risk
VYNE Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Summary
NRx Pharmaceuticals beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
